Statements

We respond to draft NICE decision to not recommend abemaciclib with fulvestrant for routine use on the NHS

The National Institute for Health and Care Excellence (NICE) has today (Friday 12 February 2021) announced its decision to provisionally not...

12 February 2021

We respond to breast cancer becoming the most common cancer globally

Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said: “Breast cancer is the most common form of cancer...

5 February 2021

We Respond to Breast Cancer Screening Performance Data for England 2019/20

New figures from NHS Digital, taken from the performance data on the breast screening programme for England between April 2019 and March 2020, show...

28 January 2021

We respond to NHS England breast cancer waiting times for November 2020

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said: “While it’s good news that November’s waiting times data...

14 January 2021

We respond to NHS England breast cancer waiting times: October 2020

NHS England cancer waiting times data from October 2020 shows: The two week wait target for people referred with suspected breast cancer was...

10 December 2020

We respond to RxPONDER trial results that suggest Postmenopausal women with early-stage BC/low recurrence score could skip adjuvant chemo

The RxPONDER trial results were presented this year at the San Antonio Breast Cancer Symposium 2020. The study was investigating if some women with...